VEGFA and hepatocellular carcinoma: Benefiting from combination treatment involving immune checkpoint inhibitors (ICIs) combined with an antivascular endothelial growth factor (anti-VEGF) monoclonal antibody, advanced HCC is considered highly treatable [2].